Initial observations of Jinhua Qinggan Granules, a Chinese medicine, in the mitigation of hospitalization and mortality in high-risk elderly with COVID-19 infection: A retrospective study in an old age home in Hong Kong.
作者信息
Lin Timothy P H, Lau Edith M C, Wan Kelvin H, Zhong Linda, Leung Enne, Ko Chung Nga, Lu Aiping, Shah Muhammad R, Bian Zhaoxiang, Lam Dennis S C
机构信息
Hong Kong Alliance of Integrated Medicine Against Covid, Hong Kong, Hong Kong SAR, China.
School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong SAR, China.
出版信息
Front Med (Lausanne). 2022 Jul 27;9:948149. doi: 10.3389/fmed.2022.948149. eCollection 2022.
Abstract
摘要
相似文献
1
Initial observations of Jinhua Qinggan Granules, a Chinese medicine, in the mitigation of hospitalization and mortality in high-risk elderly with COVID-19 infection: A retrospective study in an old age home in Hong Kong.金花清感颗粒（一种中药）对减轻新冠病毒感染高危老年人住院率和死亡率的初步观察：香港一家养老院的回顾性研究
Front Med (Lausanne). 2022 Jul 27;9:948149. doi: 10.3389/fmed.2022.948149. eCollection 2022.
2
Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients.金花清感颗粒治疗新型冠状病毒肺炎的疗效。
J Tradit Chin Med. 2020 Jun;40(3):467-472. doi: 10.19852/j.cnki.jtcm.2020.03.016.
3
Jinhua Qinggan granules for non-hospitalized COVID-19 patients: A double-blind, placebo-controlled, and randomized controlled trial.金花清感颗粒用于非住院COVID-19患者：一项双盲、安慰剂对照的随机对照试验。
Front Med (Lausanne). 2022 Aug 1;9:928468. doi: 10.3389/fmed.2022.928468. eCollection 2022.
4
Efficacy of Jinhua Qinggan Granules Combined With Western Medicine in the Treatment of Confirmed and Suspected COVID-19: A Randomized Controlled Trial.金花清感颗粒联合西药治疗新型冠状病毒肺炎确诊及疑似病例的疗效：一项随机对照试验
Front Med (Lausanne). 2021 Oct 12;8:728055. doi: 10.3389/fmed.2021.728055. eCollection 2021.
5
Network-based pharmacology and UHPLC-Q-Exactive-Orbitrap-MS reveal granule's mechanism in reducing cellular inflammation in COVID-19.网络药理学和 UHPLC-Q-Exactive-Orbitrap-MS 揭示了颗粒在降低 COVID-19 细胞炎症中的作用机制。
Front Immunol. 2024 Jul 4;15:1382524. doi: 10.3389/fimmu.2024.1382524. eCollection 2024.
6
Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway.金花清肝颗粒通过促进中性粒细胞凋亡和抑制 TLR4/MyD88/NF-κB 通路减轻急性肺损伤。
J Ethnopharmacol. 2023 Jan 30;301:115763. doi: 10.1016/j.jep.2022.115763. Epub 2022 Sep 29.
7
Jin-Zhen oral liquid for pediatric coronavirus disease (COVID-19): A randomly controlled, open-label, and non-inferiority trial at multiple clinical centers.金振口服液用于儿童冠状病毒病（COVID-19）：一项多中心随机对照、开放标签的非劣效性试验。
Front Pharmacol. 2023 Feb 27;14:1094089. doi: 10.3389/fphar.2023.1094089. eCollection 2023.
8
Efficacy and safety of Jinhua Qinggan granules for coronavirus disease 2019 (COVID-19): A protocol of a systematic review and meta-analysis.金花清感颗粒治疗新型冠状病毒肺炎（COVID-19）的疗效和安全性：一项系统评价与Meta分析方案
Medicine (Baltimore). 2020 Jun 12;99(24):e20612. doi: 10.1097/MD.0000000000020612.
9
The efficacy and safety of Jinhua Qinggan granule (JHQG) in the treatment of coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta analysis.金花清感颗粒治疗新型冠状病毒肺炎（COVID-19）的疗效与安全性：一项系统评价和Meta分析方案
Medicine (Baltimore). 2020 Jun 12;99(24):e20531. doi: 10.1097/MD.0000000000020531.
10
Potential of herbal products in prevention and treatment of COVID-19. Literature review.草药产品在预防和治疗 COVID-19 方面的潜力。文献综述。
Biomed Pharmacother. 2021 Nov;143:112150. doi: 10.1016/j.biopha.2021.112150. Epub 2021 Sep 2.
引用本文的文献
1
Practice and principle of traditional Chinese medicine for the prevention and treatment of COVID-19.中医药防治新冠肺炎的实践与原则
Front Med. 2023 Dec;17(6):1014-1029. doi: 10.1007/s11684-023-1040-8. Epub 2023 Dec 29.
2
Herbal medicine in the treatment of COVID-19 based on the gut-lung axis.基于肠-肺轴的中药治疗新型冠状病毒肺炎
Acupunct Herb Med. 2022 Sep;2(3):172-183. doi: 10.1097/HM9.0000000000000038. Epub 2022 Dec 8.
本文引用的文献
1
Jinhua Qinggan granules for non-hospitalized COVID-19 patients: A double-blind, placebo-controlled, and randomized controlled trial.金花清感颗粒用于非住院COVID-19患者：一项双盲、安慰剂对照的随机对照试验。
Front Med (Lausanne). 2022 Aug 1;9:928468. doi: 10.3389/fmed.2022.928468. eCollection 2022.
2
Specialized interferon action in COVID-19.新冠病毒中的干扰素作用机制。
Proc Natl Acad Sci U S A. 2022 Mar 15;119(11). doi: 10.1073/pnas.2116730119.
3
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
4
SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo.严重急性呼吸综合征冠状病毒2型奥密克戎变异株在人支气管和肺组织外植体中的复制
Nature. 2022 Mar;603(7902):715-720. doi: 10.1038/s41586-022-04479-6. Epub 2022 Feb 1.
5
SARS-CoV-2 Omicron spike mediated immune escape and tropism shift.严重急性呼吸综合征冠状病毒2型奥密克戎变异株刺突蛋白介导的免疫逃逸和嗜性转变。
Res Sq. 2022 Jan 17:rs.3.rs-1191837. doi: 10.21203/rs.3.rs-1191837/v1.
6
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study.南非对 SARS-CoV-2 奥密克戎变异株临床严重程度的早期评估：一项数据关联研究。
Lancet. 2022 Jan 29;399(10323):437-446. doi: 10.1016/S0140-6736(22)00017-4. Epub 2022 Jan 19.
7
Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.人类使用诱导致命突变的抗病毒核苷类似物药物治疗的遗传风险：莫努匹韦的特殊情况。
Environ Mol Mutagen. 2022 Jan;63(1):37-63. doi: 10.1002/em.22471.
8
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.莫努匹韦片用于非住院 COVID-19 患者的口服治疗。
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
9
Efficacy of Jinhua Qinggan Granules Combined With Western Medicine in the Treatment of Confirmed and Suspected COVID-19: A Randomized Controlled Trial.金花清感颗粒联合西药治疗新型冠状病毒肺炎确诊及疑似病例的疗效：一项随机对照试验
Front Med (Lausanne). 2021 Oct 12;8:728055. doi: 10.3389/fmed.2021.728055. eCollection 2021.
10
Mechanisms of SARS-CoV-2 entry into cells.SARS-CoV-2 进入细胞的机制。
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20. doi: 10.1038/s41580-021-00418-x. Epub 2021 Oct 5.
Zotero 插件